Back to Search Start Over

Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer

Authors :
Instituto de Salud Carlos III
European Commission
Carrasco, Raquel [0000-0002-2792-5316]
Trullas, Ramón [0000-0001-7951-9881]
Mengual, Lourdes [0000-0001-7418-9422]
Carrasco, Raquel
Ingelmo-Torres, Mercedes
Trullas, Ramón
Roldán, Fiorella L.
Rodríguez-Carunchio, Leonardo
Juez, Lourdes
Sureda, Joan
Alcaraz, Antonio
Mengual, Lourdes
Izquierdo, Laura
Instituto de Salud Carlos III
European Commission
Carrasco, Raquel [0000-0002-2792-5316]
Trullas, Ramón [0000-0001-7951-9881]
Mengual, Lourdes [0000-0001-7418-9422]
Carrasco, Raquel
Ingelmo-Torres, Mercedes
Trullas, Ramón
Roldán, Fiorella L.
Rodríguez-Carunchio, Leonardo
Juez, Lourdes
Sureda, Joan
Alcaraz, Antonio
Mengual, Lourdes
Izquierdo, Laura
Publication Year :
2023

Abstract

Circulating tumor DNA (ctDNA) has recently emerged as a real-time prognostic and predictive biomarker for monitoring cancer patients. Here, we aimed to ascertain whether tumor-agnostic ctDNA testing would be a feasible strategy to monitor disease progression and therapeutic response in muscle-invasive bladder cancer (MIBC) patients after radical cystectomy (RC). Forty-two MIBC patients who underwent RC were prospectively included. Blood samples from these patients were collected at different follow-up time points. Two specific mutations (TERT c.1-124C>T and ATM c.1236-2A>T) were analyzed in the patients’ plasma samples by droplet digital PCR to determine their ctDNA status. During a median follow-up of 21 months, 24% of patients progressed in a median of six months. ctDNA status was identified as a prognostic biomarker of tumor progression before RC and 4 and 12 months later (HR 6.774, HR 3.673, and HR 30.865, respectively; p < 0.05). Lastly, dynamic changes in ctDNA status between baseline and four months later were significantly associated with patient outcomes (p = 0.045). In conclusion, longitudinal ctDNA analysis using a tumor-agnostic approach is a potential tool for monitoring MIBC patients after RC. The implementation of this testing in a clinical setting could improve disease management and patients’ outcomes.

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1416002295
Document Type :
Electronic Resource